Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Conditions: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation Interventions: Drug: Everolimus; Drug: Elacestrant; Drug: Placebo; Drug: Auxiliary Medicinal Product - Dexamethasone; Drug: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues Sponsors: MedSIR; Stemline Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials